Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

被引:4
|
作者
Lin, Shin-Yi [1 ,2 ]
Kuo, Ching-Hua [2 ]
Ho, Li-Ting [3 ,4 ]
Liu, Yen-Bin [3 ,4 ]
Huang, Chih-Fen [1 ,2 ]
Tang, Sung-Chun [5 ,6 ]
Jeng, Jiann-Shing [5 ,6 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Cardiovasc Ctr, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan
关键词
atrial fibrillation; edoxaban; factor Xa inhibitors; therapeutic drug monitoring; Asians; PREDICTING STROKE; PHARMACODYNAMICS; PHARMACOKINETICS; ANTICOAGULANT; WARFARIN; OUTCOMES; RISK;
D O I
10.3389/fphar.2021.736826
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations. Methods: Participants with atrial fibrillation who were undergoing edoxaban therapy were enrolled. Peak (1-4 h after edoxaban administration) and trough (24 +/- 4 h from the last edoxaban dose) blood samples were collected to measure edoxaban concentrations using ultrahigh-performance liquid chromatography with tandem mass spectrometry. The edoxaban concentrations were compared to those observed in clinical trials to define a higher- or lower-than-expected range. Multivariate logistic regression was used to analyze the risk factors associated with high or low edoxaban concentrations. Results: Eighty participants (49 men, 61.3%) were enrolled and provided 78 trough and 76 peak samples. Twenty participants (25.6%) were determined to have low trough concentrations, which was associated with higher creatinine clearance and the use of the 30 mg regimen (odds ratio [OR] and 95% confidence interval [CI], 1.06 [1.01, 1.11], p = 0.01 and 5.77 [1.34, 24.75], p = 0.02, respectively). In contrast, 21 participants (27.6%) had high peak concentrations, which was associated with an off-label overdosing regimen (OR = 4.68 [1.23, 17.70], p = 0.02). Conclusion: Our study identified factors associated with increased or decreased edoxaban exposure. The measurement of edoxaban concentration may be recommended for patients with selected characteristics.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
    Beshir, Semira Abdi
    Chee, Kok-Han
    Lo, Yoke-Lin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (05) : 1182 - 1190
  • [2] Edoxaban in Asian Patients With Atrial Fibrillation Effectiveness and Safety
    Lee, So-Ryoung
    Choi, Eue-Keun
    Han, Kyung-Do
    Jung, Jin-Hyung
    Oh, Seil
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (08) : 838 - 853
  • [3] Edoxaban for the prevention of stroke in patients with atrial fibrillation
    Escobar Cervantes, Carlos
    Luis Merino, Jose
    Barrios, Vivencio
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (04) : 319 - 330
  • [4] The safety of edoxaban for treating atrial fibrillation
    Hammwoehner, Matthias
    Goette, Andreas
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (11) : 1295 - 1303
  • [5] Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban
    Masjuan, Jaime
    DeFelipe, Alicia
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2017, 127 (08) : 716 - 725
  • [6] Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
    Salazar, Daniel E.
    Mendell, Jeanne
    Kastrissios, Helen
    Green, Michelle
    Carrothers, Timothy J.
    Song, SaeHeum
    Patel, Indravadan
    Bocanegra, Tomas S.
    Antman, Elliott M.
    Giugliano, Robert P.
    Kunitada, Satoshi
    Dornseif, Bruce
    Shi, Minggao
    Tachibana, Masaya
    Zhou, Simon
    Rohatagi, Shashank
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 925 - 936
  • [7] Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease
    Qamar, Arman
    Antman, Elliott M.
    Ruff, Christian T.
    Nordio, Francesco
    Murphy, Sabina A.
    Grip, Laura T.
    Greenberger, Norton J.
    Yin, Ophelia Q. P.
    Choi, Youngsook
    Lanz, Hans J.
    Mercuri, Michele F.
    Braunwald, Eugene
    Giugliano, Robert P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (02) : 179 - 189
  • [8] Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation
    Weitz, Jeffrey I.
    Eikelboom, John
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (02) : 257 - 270
  • [9] Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation
    Lin, Shin-Yi
    Liu, Yen-Bin
    Ho, Li-Ting
    Peng, Yu-Fong
    Kuo, Ching-Hua
    Tang, Sung-Chun
    Huang, Chih-Fen
    Jeng, Jiann-Shing
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (08) : 776 - 784
  • [10] Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
    Carnicelli, Anthony P.
    De Caterina, Raffaele
    Halperin, Jonathan L.
    Renda, Giulia
    Ruff, Christian T.
    Trevisan, Marco
    Nordio, Francesco
    Mercuri, Michele F.
    Antman, Elliott
    Giugliano, Robert P.
    CIRCULATION, 2017, 135 (13) : 1273 - 1275